Abstract
Di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone possesses potent and selective antitumor activity. Its cytotoxicity has been attributed to iron chelation leading to inhibition of the iron-containing enzyme ribonucleotide reductase (RR). Thiosemicarbazone iron complexes have been shown to be redox-active, although their effect on cellular antioxidant systems is unclear. Using a variety of antioxidants, we found that only N-acetylcysteine significantly inhibited thiosemicarbazone-induced antiproliferative activity. Thus, we examined the effects of thiosemicarbazones on major thiol-containing systems considering their key involvement in providing reducing equivalents for RR. Thiosemicarbazones significantly (p < 0.001) elevated oxidized trimeric thioredoxin levels to 213 ± 5% (n = 3) of the control. This was most likely due to a significant (p < 0.01) decrease in thioredoxin reductase activity to 65 ± 6% (n = 4) of the control. We were surprised to find that the non–redox-active chelator desferrioxamine increased thioredoxin oxidation to a lower extent (152 ± 9%; n = 3) and inhibited thioredoxin reductase activity (62 ± 5%; n = 4), but at a 10-fold higher concentration than thiosemicarbazones. In contrast, only the thiosemicarbazones significantly (p < 0.05) reduced the glutathione/oxidized-glutathione ratio and the activity of glutaredoxin that requires glutathione as a reductant. All chelators significantly decreased RR activity, whereas the NADPH/NADPtotal ratio was not reduced. This was important to consider because NADPH is required for thiol reduction. Thus, thiosemicarbazones could have an additional mechanism of RR inhibition via their effects on major thiol-containing systems.
Footnotes
↵
The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.
This work was supported by the National Health and Medical Research Council of Australia [Grants 570952, 570829]; the National Heart Foundation Fellowship [CR08S 3959]; and the Cancer Institute New South Wales [Research Scholar Award 07/RSA/1-33, Early Career Development Fellowships 08/ECF/1-36].
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
doi:10.1124/mol.111.071324.
-
ABBREVIATIONS:
- ROS
- reactive oxygen species
- ATO
- arsenic trioxide
- BCNU
- bis-chloronitrosourea
- Bp44mT
- 2-benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone
- Bp4eT
- 2-benzoylpyridine-4-ethyl-3-thiosemicarbazone
- BSO
- buthionine sulfoximine
- DFO
- desferrioxamine
- Dp44mT
- di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone
- DTT
- dithiothreitol
- EPR
- electron paramagnetic resonance
- GR
- glutathione reductase
- Grx
- glutaredoxin
- GSH
- glutathione
- GSSG
- oxidized glutathione
- NAC
- N-acetylcysteine
- RR
- ribonucleotide reductase
- SOD
- superoxide dismutase
- TfR1
- transferrin receptor-1
- Trx
- thioredoxin
- TrxR
- thioredoxin reductase
- Trx
- thioredoxin
- PKIH
- pyridylketone isonicotinoyl hydrazone.
- Received January 21, 2011.
- Accepted March 9, 2011.
- Copyright © 2011 The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|